Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert’s syndrome
Abstract Liver-related side effects are a known complication of treatment with elexacaftor/tezacaftor/ivacaftor (ETI) for cystic fibrosis (CF). Gilbert’s syndrome is caused by a genetic mutation that reduces activity of the enzyme UDP glucuronosyltransferase 1 polypeptide A1 (UGT1A1), causing elevat...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2024-07-01
|
| シリーズ: | BMC Pulmonary Medicine |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12890-024-03114-6 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|